Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients.

Content Provider	Europe PMC
Author	Wang, Chao Liu, Xiang Li, Hongyan Zhao, Libo Kong, Guanyi Chen, Jing Li, Zhi Qi, Jianfei Tian, Ye Zhang, Fengbo
Copyright Year	2022
Abstract	BackgroundAndrogen receptor variant 7 (AR-V7) detection provides important information for the clinical management of abiraterone in metastatic castration-resistant prostate cancer (mCRPC). We performed a non-invasive urine-derived exosomal AR-V7 analysis of mCRPC patients.MethodsA total of 34 mCRPC patients were recruited including 16 patients treated with abiraterone (ABI) with stable prostate-specific antigen (PSA)/radiograph response (the ABI-Sta group) and 18 were resistant to abiraterone (the ABI-Res group). Urine was collected from patients and healthy control patients for the analysis. Exosomal ribonucleic acid was isolated from urine. Urinary exosome-based androgen receptor-variant 7 was detected by quantitative real-time polymerase chain reaction assay. Characteristics of patients and survival data were collected. The correlation between AR-V7 expression and the therapeutic effect/survival outcomes of abiraterone was analyzed.ResultsUrine is the ideal biological sample for exosome separation and AR full-length analysis. Positive urine-derived exosomal AR-V7 was detected in 32.4% (11 of 34) of the mCRPC patients’ urine samples. Positive AR-V7 was more common in the ABI-Res patients than the ABI-Sta patients (50.0% vs. 12.5%, respectively; P=0.009), and was associated with a higher PSA progression rate and poorer overall survival (OS) (P=0.0031, and P=0.0012, respectively).ConclusionsThe present study showed that the detection of urine-derived exosomal AR-V7 provides a sensitive and feasible clinical workflow. The predicting role of urine-derived exosomal AR-V7 in mCRPC patients should be further verified using studies with greater sample sizes.
ISSN	22234683
Journal	Translational Andrology and Urology
Volume Number	11
PubMed Central reference number	PMC8899142
Issue Number	2
PubMed reference number	35280667
e-ISSN	22234691
DOI	10.21037/tau-21-1136
Language	English
Publisher	AME Publishing Company
Publisher Date	2022-02-01
Access Restriction	Open
Rights License	Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0. 2022 Translational Andrology and Urology. All rights reserved.
Subject Keyword	Androgen receptor (AR) splicing variant castration-resistant prostate cancer (PCa) abiraterone exosome
Content Type	Text
Resource Type	Article
Subject	Urology Reproductive Medicine